article · Scientific African
This study evaluated the antihypertensive properties of leaf extracts of Prosopis africana (PA) in vitro and in hypertensive rats. Ethanol (ELPA) and differential solvent fractions [ethyl-acetate (EAPA), butanol (BLPA), and aqueous (ALPA)] were prepared using standard protocols. Hypertension was induced in female albino Wistar rats intraperitoneally using cyclosporine (25 mg/kg/day) while extracts were administered via oral route. Forty female rats were grouped into 5 ( n = 8). Group 1 received 2 ml distilled water, Group 2: (cyclosporine + 2 ml distilled water); Group 3: cyclosporine + captopril (10 mg/kg/day); Group 4: cyclosporine + 1000 mg/kg ELPA and Group 5: cyclosporine + 1500 mg/kg ELPA. The blood pressure of anesthetized rats was measured using LabScribe coupled to a Lab-Trax-4/24T, and the activities of angiotensin-converting enzyme (ACE), arginase, phosphodiesterase-5 (PDE-5), acetylcholinesterase (AChE) and adenosine deaminase (ADA) were evaluated using standard methods. All the fractions exerted significantly ( p < 0.05) higher ACE inhibitory effect (ELPA = 64.36 ± 0.50%; EAPA = 86.31 ± 0.60%; BLPA= 85.28 ± 2.30 % ; ALPA= 82.27 ± 2.10 % ) than the reference, lisinopril (40.22±0.50 % ); while the butanol fraction (67.05±0.40 % ) showed higher PDE-5 inhibition than the reference, sildenafil (23.06±0.70 % ). Administration of cyclosporine caused notable ( p < 0.05) elevation of systolic/diastolic blood (131.00 ± 1.22/93.25 ± 1.49 mmHg) pressure plus elevated heart rate when in comparison with the normotensive rats (106.25 ± 1.65/85.25 ± 1.18 mmHg). Treatment of hypertensive rats with ELPA significantly reduced elevated activities of ACE, PDE-5, AChE, and arginase to values that are not significantly ( p < 0.05) different from those of the rats treated with the reference drug. This result could validate the use of P. africana as an antihypertensive agent in folklore.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.sciaf.2024.e02487
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.